CD55 gene therapy - Imutran

Drug Profile

CD55 gene therapy - Imutran

Alternative Names: Decay-accelerating factor gene therapy - Imutran

Latest Information Update: 01 Sep 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Imutran
  • Class Gene therapies
  • Mechanism of Action CD55 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Xenotransplant rejection

Most Recent Events

  • 01 Sep 1998 No-Development-Reported for Xenotransplant rejection in United Kingdom (Unknown route)
  • 03 Dec 1996 New profile
  • 03 Dec 1996 Preclinical development for Xenotransplant rejection in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top